Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
125 studies found for:    regorafenib
Show Display Options
Rank Status Study
1 Not yet recruiting Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
Conditions: Metastatic Solid Malignancies;   Locally Advanced Solid Malignancies
Intervention: Drug: Regorafenib
2 Recruiting [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Condition: Colorectal Cancer
Intervention: Drug: Regorafenib
3 Active, not recruiting Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
Condition: Advanced Chemorefractory Colorectal Adenocarcinoma
Intervention: Drug: regorafenib
4 Recruiting Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Regorafenib
5 Recruiting Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Conditions: Pancreas Cancer;   Ovarian Cancer;   Melanoma;   Sarcoma
Intervention: Drug: Regorafenib
6 Recruiting Phase II Study of Perindopril and Regorafenib in mCRC
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib;   Drug: Perindopril
7 Not yet recruiting Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Condition: Acute Myeloid Leukemia
Intervention: Drug: Regorafenib
8 Active, not recruiting
Has Results
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: regorafenib
9 Active, not recruiting Regorafenib Post-marketing Surveillance
Condition: Colorectal Neoplasms
Intervention: Drug: BAY73-4506_Regorafenib
10 Recruiting Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Condition: Cancer of the Bile Duct
Intervention: Drug: Regorafenib
11 Recruiting Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Regorafenib;   Drug: Sildenafil Citrate
12 Recruiting A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
Condition: Colon Cancer
Intervention: Drug: Regorafenib
13 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
14 Recruiting A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: Regorafenib
15 Recruiting Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Condition: Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Intervention: Drug: Regorafenib
16 Active, not recruiting Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73- 4506)
17 Recruiting Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Drug: Regorafenib
18 Recruiting Efficacy of Ginseng for Patients on Regorafenib
Conditions: Colorectal Cancer;   Palliative Medicine;   Supportive Care
Interventions: Drug: Regorafenib;   Dietary Supplement: Ginseng
19 Completed Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: PF-03446962;   Drug: Regorafenib
20 Recruiting A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Condition: Metastatic Biliary Tract Carcinoma
Intervention: Drug: Regorafenib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.